Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Ovarian Neoplasms 3Multiple Myeloma 3Lymphoma 3Urinary Bladder Neoplasms 2Lung Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Sarcoma, Synovial 1Recurrent Lung Squamous Cell Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neoplasm Metastasis 1Meningeal Neoplasms 1Melanoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Fibrolamellar hepatocellular carcinoma 1

Interventions

Doxorubicin 5Specimen Handling 4Radiotherapy 4Magnetic Resonance Spectroscopy 3Biopsy 3pazopanib 2Radiation 2Nivolumab 2Ipilimumab 2Ifosfamide 2CTLA-4 Antigen 2talimogene laherparepvec 1saracatinib 1sapanisertib 1romidepsin 1peposertib 1pembrolizumab 1montanide ISA 51 1liposomal doxorubicin 1cixutumumab 1cabozantinib 1X-Rays 1Temozolomide 1Sorafenib 1Ritonavir 1Molecular Diagnostic Techniques 1Microarray Analysis 1MLN 8237 1Interleukin-2 1Indinavir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Histiocytoma, Malignant Fibrous × sapanisertib × Clear all
NCT02601209 2022-08-23

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
151 enrolled 22 charts
Sarcoma

Leiomyosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡